Skip to Content

Join the 'Non-Hodgkin's Lymphoma' group to help and get support from people like you.

Non-Hodgkin's Lymphoma News

Related terms: Cancer, Non-Hodgkin's Lymphoma, Histiocytic Lymphoma, Lymphoblastic Lymphoma, Lymphocytic Lymphoma, Lymphoma, Histiocytic, Lymphoma, Lymphoblastic, Lymphoma, Lymphocytic, Lymphoma, Non-Hodgkin's, Non-Hodgkin Lymphoma

Why Fewer Blacks and Hispanics Survive Some Childhood Cancers

Posted 22 Aug 2018 by Drugs.com

WEDNESDAY, Aug. 22, 2018 – Poverty is a major reason black and Hispanic children with some types of cancer have lower survival rates than white patients, a new study finds. Researchers examined U.S. government data on nearly 32,000 black, Hispanic and white children who were diagnosed with cancer between 2000 and 2011. For several cancers, whites were much more likely to survive than blacks and ...

New Treatment for Non-Hodgkin Lymphoma Approved

Posted 8 Aug 2018 by Drugs.com

WEDNESDAY, Aug. 8, 2018 – Poteligeo (mogamulizumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with two types of non-Hodgkin lymphoma. The drug was approved to treat relapsed or refractory mycosis fungoides (MF) and Sézary syndrome (SS) after the patient has had at least one prior therapy delivered through the bloodstream. "Mycosis fungoides and Sézary s ...

FDA Approves Keytruda (pembrolizumab) for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Posted 18 Jun 2018 by Drugs.com

KENILWORTH, N.J.--(BUSINESS WIRE) June 13, 2018 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, the company’s anti-PD-1 therapy, for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more p ...

Kymriah (tisagenlecleucel) Receives Second FDA Approval to Treat Appropriate Patients with Large B-Cell Lymphoma

Posted 4 Jun 2018 by Drugs.com

Basel, May 1, 2018 - Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication - the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL), high grade B-cell ...

Get Active, Beat Lymphoma?

Posted 12 Dec 2017 by Drugs.com

TUESDAY, Dec. 12, 2017 – Physical activity appears to help people with lymphoma survive their disease. That finding comes from a new study by Mayo Clinic researchers of nearly 4,100 people with lymphoma, a cancer that starts in the white blood cells that normally help fight infection. "As physicians, we recommend physical activity for all cancer survivors to improve overall quality of life, but ...

FDA Approves 2nd Gene Therapy Yescarta

Posted 19 Oct 2017 by Drugs.com

THURSDAY, Oct. 19, 2017 – The U.S. Food and Drug Administration has approved the second gene therapy for use in the United States. The new treatment, Yescarta (axicabtagene ciloleucel), is for a kind of blood cancer called large B-cell lymphoma. The treatment is known as chimeric antigen receptor (CAR) T cell therapy, and is only the second such therapy sanctioned by the FDA. In August, the ...

Gene Therapy, Yescarta (axicabtagene ciloleucel), Approved for B-Cell Lymphoma

Posted 19 Oct 2017 by Drugs.com

THURSDAY, Oct. 19, 2017 --Yescarta (axicabtagene ciloleucel) has been approved by the U.S. Food and Drug Administration as the first form of gene therapy for a non-Hodgkin lymphoma (NHL) form of cancer. Diffuse large B-cell lymphoma is the most common form of this immune system cancer in adults, the agency said in a news release. Some 72,000 cases of NHL are diagnosed each year in the United ...

FDA Approves Yescarta (axicabtagene ciloleucel) CAR-T Cell Therapy to Treat Adults with Certain Types of Large B-Cell Lymphoma

Posted 19 Oct 2017 by Drugs.com

October 18, 2017 – The U.S. Food and Drug Administration today approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the ...

Childhood Cancer Survivors Now Living Healthier Lives

Posted 2 Jun 2017 by Drugs.com

FRIDAY, June 2, 2017 – For people who battled cancer in childhood, the prospects for a long life without cancer recurrence or chronic illness are better than ever, a new study finds. That's largely due to changes in cancer treatment protocols that have meant less toxicity to children and less chance for long-term side effects, researchers said. This is the first "comprehensive" study on the ...

Cancer Risk Rises After Childhood Organ Transplant: Study

Posted 26 Apr 2017 by Drugs.com

WEDNESDAY, April 26, 2017 – Children given an organ transplant have a substantially higher risk of developing cancer – in some cases up to 200 times higher – than the general population, a new study finds. But the individual risk of any one child getting cancer still remains very small, the study authors stressed. Overall, the U.S. National Cancer Institute (NCI) study found that the risk for ...

Gene Therapy Shows Promise for Aggressive Lymphoma

Posted 28 Feb 2017 by Drugs.com

TUESDAY, Feb. 28, 2017 – An experimental gene therapy for aggressive non-Hodgkin lymphoma beat back more than a third of cancers that seemed untreatable, the therapy's developers report. Thirty-six percent of over 100 very ill lymphoma patients appeared disease-free six months after a single treatment, according to results released by the treatment's maker, Kite Pharma of Santa Monica, Calif. ...

DNA Sequencing May Lead to Personalized Cancer Treatment

Posted 9 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 9, 2016 – DNA sequencing may help personalize treatment for people with lymphoma, a new study suggests. By analyzing small bits of DNA in the blood, researchers at Stanford University School of Medicine said they could determine the cancer's subtype. They said they could also identify mutations that might make treatment less effective or worsen a patient's prognosis. The study ...

Immune Therapy Makes Headway Against a Lymphoma

Posted 8 Sep 2016 by Drugs.com

THURSDAY, Sept. 8, 2016 – Genetically engineered immune cells appear capable of eradicating non-Hodgkin lymphoma when coupled with effective chemotherapy, a new early trial finds. In this experimental therapy, white blood cells known as T-cells are removed from the patient's bloodstream. Then they're genetically modified so they can detect and attack cancerous B-cells, another type of white ...

Stem Cell Transplant Can Help HIV Patients Battling Lymphoma: Study

Posted 15 Jun 2016 by Drugs.com

WEDNESDAY, June 15, 2016 – People living with HIV are at high risk for lymphoma, and a new study concludes that stem cell transplant should be standard treatment in these cases. The transplants should be "autologous" – meaning the cells come from the patients themselves, the researchers said. The new findings could challenge the widely held belief that HIV-positive patients are not candidates ...

FDA Medwatch Alert: BiCNU (carmustine for injection): FDA Alert - Counterfeit Product Discovered in Some Foreign Countries

Posted 16 May 2016 by Drugs.com

ISSUE: FDA is informing health care professionals that a counterfeit version of the FDA approved cancer drug, BiCNU (carmustine for injection) 100 mg, has been detected in some foreign countries. There is no indication at this time that counterfeit BiCNU has entered the legitimate U.S. drug supply chain and no indication that any U.S. patients have received counterfeit BiCNU. See the FDA Alert ...

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

B Cell Lymphoma, T Cell Lymphoma, Lymphoma

Related Drug Support Groups

methotrexate, Rituxan, rituximab, Imbruvica, Cytoxan, bendamustine, cyclophosphamide, ibrutinib, Treanda, view more... cytarabine, vincristine, Zevalin, Methotrexate LPF Sodium, Cytosar-U, bleomycin, Fludara, Cytosar, ibritumomab, Bendeka, Neosar, In-111 Zevalin, Oncovin, Y-90 Zevalin, Bexxar Dosimetric, Bexxar, Mozobil, BexxarTherapeutic, Oforta, Folotyn, Zydelig, Tarabine PFS, Novantrone, Folex PFS, pralatrexate, fludarabine, mitoxantrone, teniposide, tositumomab / iodine i 131 tositumomab, plerixafor, tositumomab, idelalisib, Cytoxan Lyophilized, Blenoxane, BiCNU, Gliadel, Trexall, carmustine, Vumon, Vincasar PFS, Bleo 15k